Citi adjusts MedTech outlook: Bullish on Haemonetics, bearish on Tandem Diabetes Investing.com -- Citi analysts have taken action on two U.S. MedTech names, upgrading Haemonetics (NYSE:HAE) to Buy from Neutral, while downgrading Tandem Diabetes Care (NASDAQ:TNDM) to Sell/High Risk from Neutral/High Risk, citing diverging prospects in the second half of 2025. On Haemonetics, Citi sees a more derisked outlook following the company’s fiscal 2026 guidance. “With HAE FY26 guidance clearing the hurdle, the path forward is more derisked as Plasma share gains are baked into contracts,” analysts wrote. Citi now expects high single-digit core revenue growth (ex-CSL) and margin expansion to deliver high-teens EPS growth, raising its price target to $90 from $71. In contrast, Tandem is said to face mounting headwinds. “While the 2Q25 delivery will be imperative, commentary on competition and the impact of potential competitive bidding will be top of mind,” Citi noted. The firm believes these factors will keep the stock under pressure and downgraded TNDM to Sell, slashing its price target from $24 to $14. Citi’s broader outlook on the MedTech sector remains constructive. While tariff-related uncertainty continues to cloud guidance, analysts are embracing a “return to fundamentals with several catalysts providing momentum in 2H25+.” Notably, the bank continues to favor BSX and EW as Top Picks and initiated a positive catalyst watch on GE Healthcare and Intuitive Surgical (NASDAQ:ISRG). Despite macro volatility, Citi said the sector is outperforming its healthcare peers, noting the S&P Equipment & Supplies Index is up 7.2% year-to-date versus Biotechnology at 5.7% and Pharmaceuticals down 3.7%. With ISRG making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed ISRG alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including ISRG, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is ISRG poised for similar growth? Don't miss the opportunity to find out.

Click Subscribe #MedTech #Investing #HealthcareStocks #Haemonetics #TandemDiabetes

Tandem Diabetes stock falls after Citi downgrades to Sell on competition concerns Investing.com -- Tandem Diabetes Care (NASDAQ:TNDM) stock fell 5% Wednesday morning after Citi downgraded the medical device maker to Sell from Neutral, citing intensifying competitive pressures. Analyst Joanne Wuensch slashed the price target to $14 from $24, implying a potential 16% downside from Tuesday’s closing price of $16.62. The downgrade triggered selling in premarket trading as investors digested concerns about the company’s growth prospects. "While the 2Q25 delivery will be imperative, commentary on competition and the impact of potential competitive bidding will be top of mind," Wuensch wrote in a note to clients. She added that competition remains stiff and sees potential pressures from competitive bidding. The analyst expressed skepticism about Tandem’s ability to overcome these challenges in the near term. "With these competing pressures, we believe it will be difficult for TNDM to trade upwards, and likely will remain pressured," Wuensch noted. Tandem Diabetes Care manufactures insulin delivery systems for people with diabetes, operating in a market with several established competitors. The company faces headwinds not only from existing rivals but also potential pricing pressures from competitive bidding processes in the medical device sector. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks – 6 model portfolios fueled by AI stock picks with a stellar performance this year.. In 2024 alone, ProPicks' AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if TNDM is on your watchlist, it could be very wise to know whether or not it made the ProPicks lists.

Click Subscribe #TandemDiabetes #StockMarket #Investing #Citi #SellRating

Tandem Diabetes Care t:slim X2 insulin pump displaying the Control-IQ+ interface, showing a glucose trend graph, insulin on board, bolus details, and current blood glucose level on its touchscreen.

Tandem Diabetes Care has received FDA clearance for its Control-IQ+ automated insulin delivery system for adults with type 2 diabetes. U.S. availability expected in March 2025.

jcst2d.com/index.php?vi...

#TandemDiabetes #FDAApproval #Type2Diabetes #InsulinDelivery

I cannot wait until I'm able to transition to the G7 with its faster warm up time.

Come on Canada Health & Tandem! Get your shit together.

#diabetic #dexcom #tandemdiabetes

FDA recalls faulty iOS app that injured hundreds of insulin pump users The US Food and Drug Administration has issued a Class 1 recall for an iOS app that interfaces with an insulin pump due to a software glitch...

The FDA has issued a Class 1 recall for an iOS app that interfaces with an insulin pump due to a software glitch causing the app to crash and automatically restart

#FDA #recall #apple #ios #iphone #TandemDiabetes #insulin #diabetes #healthcare #technology #tech

www.techspot.com/news/102962-...